Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
The biology of roginolisib: Activity without immune toxicity
Industry Insight
End of year reflections from our CEO
Industry Insight
Driving breakthroughs for myelofibrosis care
Industry Insight
What’s next for cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura expands roginolisib trials to the US
Industry Insight
iOnctura enhances board to accelerate growth and innovation
Industry Insight
Addressing drug resistance in non-small cell lung cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
Download our corporate deck
Find out more about our mission to give patients more momets that matter
All news
Press release
iOnctura Expands Roginolisib Trials to the US, Advancing Multi-Indication Strategy in Oncology
Press coverage
Biotech TV – Interview with Catherine Pickering
Press coverage
OncLive – Early Activity With Roginolisib Supports Ongoing Phase 2 OCULE-01 Trial in Metastatic Uveal Melanoma
Press release
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
Data & publication
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Data & publication
A Randomised Phase II Study of Roginolisib in Patients With Advanced / Metastatic Ocular / Uveal Melanoma (OCULE-01)
Press release
iOnctura bolsters leadership team with new appointments
Press coverage
Pharma Boardroom – Interview with Catherine Pickering
Press release
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
Press coverage
Careers in Discovery Podcast – Lars van der Veen, iOnctura
Data & publication
Molecular profiling of the PI3Kδ inhibitor roginolisib in metastatic uveal melanoma and its correlation with clinical outcomes
Press release
iOnctura commences randomized Phase II study in metastatic uveal melanoma
Looking for media
resources?